Multiple myeloma (MM) is a clonal plasma cell disorder arising from the bone marrow and is the second most common hematologic malignancy in the United States (US), with an incidence of approximately 35,000 new cases per year. While progression-free survival (PFS) benefit is often seen with MM therapeutics, overall survival (OS) benefit is rarely seen with novel therapies, and improvements in PFS are still associated with adverse events and long-term disease refractoriness. Over the past few decades, rigorous pre-clinical and clinical research has led to the discovery of novel therapies that have dramatically changed the treatment landscape of MM in the frontline as well as in the relapsed/refractory setting. Despite implementing multimodal approaches to treat MM, the major challenge remains that the vast majority of patients eventually relapse and become refractory to multiple drug classes. Additionally, patients require continuous treatment throughout the disease course, which can negatively affect their quality of life due to potential therapy-related side effects. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with multiple myeloma.
CME/CE Accreditation Information
The goal of this initiative is to improve the care of patients with Duchenne muscular dystrophy (DMD). DMD is the most common childhood form of muscular dystrophy and characteristic manifestations are progressive muscle weakness, cardiorespiratory impairment, and premature death. Gene therapy provides a new avenue to treat life‐limiting neuromuscular disorders. Given the novelty of these therapies, clinicians involved in the care of patients with DMD may not be aware of their associated evidence and implementation. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with Duchenne muscular dystrophy.
CME/CE Accreditation Information
This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.
CME/CE Accreditation Information
It is well recognized that early diagnosis and ongoing management of Alzheimer’s Disease (AD) requires a patient-centric, highly coordinated effort among a large multidisciplinary team of clinicians. As such, this proposed initiative establishes meaningful, small group interactions among key stakeholders (neurologists, dementia specialists, geriatricians, geriatric psychologists, radiologists, and primary care clinicians) that will, through a variety of collaborative educational experiences, help all members of the care team consider approaches to reducing barriers to effective coordinated care and encourages each participant to create an action plan to improve the quality of AD care delivered within their organization. Considering the complexity of this challenge, lack of expertise, and the breadth of communication and cooperation required, participants would highly benefit from an educational intervention that includes discussions with knowledgeable experts and peers from within and outside of their own communities who can share experiences, strategies, challenges, and success stories.
CME/CE Accreditation Information
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).
CME/CE Accreditation Information
Endometrial cancer is among the few cancers increasing in incidence and mortality in the United States. In its early stages, endometrial carcinoma has a five-year relative survival rate of 96%, but it decreases to 18% for those with metastases. Surprisingly, mortality has been increasing faster than incidence. This is attributed to increasing rates of advanced cancers, higher-risk histologies, and older age of first diagnosis. Yet, there have also been increases in diagnoses in women aged less than 50 years, based on Surveillance, Epidemiology, and End Results (SEER) program data.
While the incidence and mortality has been increasing across all racial groups, the rate of increase for Black women has been the steepest. Adjusting for the higher rate of hysterectomy in Black women compared with White women, the differing rates of this cancer in these groups exemplify this racial disparity.
These statistics demonstrate the need for new therapeutics and subsequent education on their use in this field. To improve clinical outcomes, clinicians treating patients for advanced/recurrent endometrial cancer need to understand biomarker testing and molecular classification of disease, newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events. To these ends, this educational initiative will allow clinicians managing patients with advanced/recurrent endometrial cancer to learn and discuss the crucial points in diagnosing and managing these patients to best increase long-term survival.
CME/CE Accreditation Information
Immunotherapy, which has demonstrated benefits in advanced and metastatic settings, is moving into early non-small cell lung cancer treatment, expanding options for patients with resected or resectable early-stage non-small cell lung cancer. This rapid evolution of the early NSCLC treatment landscape, while exciting, has created clinical challenges as health care providers struggle with translating these clinical trial results into real-world clinical practices in the adjuvant and neoadjuvant settings. This educational initiative establishes impactful small group interactions among oncology care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with early-stage NSCLC.
CME/CE Accreditation Information
The current treatment of advanced, recurrent, and metastatic cervical cancer is difficult, especially as treatment progresses to the second line. Considerations for treatment are nuanced and numerous. Factors include prior treatments, treatment timing, and patient preference. The advent of targeted therapies has brought improved outcomes for those patients whose tumors harbor specific mutations. Still for those who are ineligible for targeted therapies, currently available options are lacking. Agents in the pipeline of development and potential approval offer hope for the treatment of this difficult to manage disease. The goal of this educational curriculum, Turning Complexity into Clarity in Advanced Cervical Cancer, is to establish impactful small group interactions between members of the cervical cancer care team that will, through a variety of collaborative educational experiences, help them in learning and sharing best practices that will improve outcomes for patients with cervical cancer.
CME/CE Accreditation Information
Acute myeloid leukemia (AML) continues to be the most common acute leukemia in adults, with an incidence of 5.5 cases per 100,000 persons annually. As such, more education is needed on key topics including use of induction therapy in the non-elderly population, treating suboptimal response to induction therapy, best practices for measurable (or minimal) residual disease assessment, and proper use of maintenance therapy..The goal of this educational curriculum, Turning Complexity into Clarity in AML, is to establish impactful small group interactions between members of the AML care team that will, through a variety of collaborative educational experiences, help them in learning and sharing best practices that will improve outcomes for patients with AML.
CME/CE Accreditation Information
Often seen in Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), arise as a consequence of immune system involvement and can have myriad health consequences. Both CIDP and MMN are characterized by complex presentations and frequent misdiagnoses. CIDP shows gradual peripheral nerve demyelination, leading to weakness and sensory loss, while MMN presents with asymmetric weakness devoid of sensory complications. With an array of treatment options, managing polyneuropathy in CIDP and MMN can be challenging. This collaborative platform serves as a unifying space for healthcare providers, facilitating the exchange of insights and elevating the standard of care for patients affected by CIDP and MMN. In this learning activity, you will learn how to enhance the lives of CIDP and MMN patients via a program promoting local and cross-community support, driving effective practice-sharing for better outcomes.
CME/CE Accreditation Information
